Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026)

Johnson & Johnson (JNJ) posted Cash from Investing Activities of -$1.0 billion for Q1 2026, up 76.81% sequentially from -$4.5 billion in Q4 2025, and down 250.17% YoY from $692.6 million in Q1 2025.

Johnson & Johnson (JNJ) Cash from Investing Activities (2009 - 2026) Analysis & Trends

Johnson & Johnson (JNJ) has 18 years of Cash from Investing Activities data on file, last reported at -$1.0 billion in Q1 2026.

  • Quarterly Cash from Investing Activities fell 250.17% year-over-year to -$1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$24.3 billion (down 32.0% YoY) and the FY2025 annual result came in at -$23.6 billion, down 26.82% from the prior year.
  • Cash from Investing Activities rose to -$1.0 billion in Q1 2026 per JNJ's latest filing, from -$4.5 billion in the prior quarter.
  • The five-year high for Cash from Investing Activities was $3.3 billion in Q2 2023, with the low at -$18.3 billion in Q2 2025.
  • Average Cash from Investing Activities over 5 years is -$3.7 billion, with a median of -$1.3 billion recorded in 2024.
  • Year-over-year, Cash from Investing Activities slumped 1864.32% in 2022 and soared 191.22% in 2023.
  • Johnson & Johnson's Cash from Investing Activities stood at -$3.6 billion in 2022, then surged by 66.92% to -$1.2 billion in 2023, then slipped by 9.82% to -$1.3 billion in 2024, then slumped by 239.77% to -$4.5 billion in 2025, then soared by 76.81% to -$1.0 billion in 2026.
  • Business Quant data shows JNJ's Cash from Investing Activities at -$1.0 billion in Q1 2026, -$4.5 billion in Q4 2025, and -$542.0 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing (Qtr)
1 Eli Lilly 1,066.16 Bn 1,060.88 Bn 16.22 Bn -3.92 Bn
2 Johnson & Johnson 611.69 Bn 589.64 Bn 15.96 Bn -1.04 Bn
3 AbbVie 444.34 Bn 434.99 Bn 10.78 Bn -574.00 Mn
4 Astrazeneca 284.94 Bn 277.05 Bn 12.61 Bn -1.79 Bn
5 Merck 224.23 Bn 218.58 Bn 12.09 Bn -10.21 Bn
6 Amgen 195.12 Bn 183.08 Bn 5.87 Bn -716.00 Mn
7 Gilead Sciences 156.45 Bn 148.73 Bn 5.52 Bn 1.77 Bn
8 Pfizer 136.01 Bn 123.24 Bn -1.21 Bn 785.00 Mn
9 Novartis Ag 113.45 Bn 113.67 Bn - -
10 Biogen 30.87 Bn 26.59 Bn 1.82 Bn -209.50 Mn

Historic Data

Download Data
DateValue
Mar 29, 2026 -1.04 Bn
Mar 29, 2026 -1.04 Bn
Dec 28, 2025 -4.49 Bn
Dec 28, 2025 -4.49 Bn
Sep 28, 2025 -542.00 Mn
Sep 28, 2025 -542.00 Mn
Jun 29, 2025 -18.26 Bn
Jun 29, 2025 -18.26 Bn
Mar 30, 2025 -297.00 Mn
Mar 30, 2025 -297.00 Mn
Dec 29, 2024 -1.32 Bn
Dec 29, 2024 -1.32 Bn
Sep 29, 2024 -3.13 Bn
Sep 29, 2024 -3.13 Bn
Jun 30, 2024 -13.69 Bn
Jun 30, 2024 -13.69 Bn
Mar 31, 2024 -464.00 Mn
Mar 31, 2024 -464.00 Mn
Dec 31, 2023 -1.20 Bn
Dec 31, 2023 -1.20 Bn